CPI

TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint Resistant Metastatic Melanoma Phase I Trial at ESMO Immuno-Oncology 2023

Retrieved on: 
Friday, December 8, 2023
Immunotherapy, TILT, TIL, ESMO, Neoplasm, Tumor microenvironment, University of Copenhagen, Injection, Interleukin, Congress, News, Cancer, CPI, Patient, Potyvirus, Safety, TILS, SITC, Pharmaceutical industry

This is the first-time clinical data with an oncolytic virus in combination with tumor infiltrating lymphocyte therapy has been presented.

Key Points: 
  • This is the first-time clinical data with an oncolytic virus in combination with tumor infiltrating lymphocyte therapy has been presented.
  • TILT’s approach uses oncolytic viruses to selectively replicate in and lyse cancer cells, while simultaneously stimulating immune responses towards the tumor.
  • The data announcement at ESMO-IO relates to 16 patients with checkpoint inhibitor (CPI) resistant progressive metastatic melanoma, who were treated with multiple intravenous and intratumoral injections of TILT-123 and a one- or two- time treatment with TILs.
  • The company has several trials currently underway, reflecting its commitment to pushing the boundaries of cancer treatment (NCT04217473, NCT05271318, NCT05222932).

BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

Retrieved on: 
Wednesday, December 6, 2023
Survival, Probability, Allogenic succession, Kaplan–Meier estimator, BCT, NLR, Cancer, Therapy, CPI, University, Lymphocyte, Toxicity, TSX, Patient, Pharmaceutical industry

32 out of 42 patients treated since 2022 remain alive suggesting consistently strong survival benefit.

Key Points: 
  • 32 out of 42 patients treated since 2022 remain alive suggesting consistently strong survival benefit.
  • PHILADELPHIA and VANCOUVER, British Columbia, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is thrilled to announce continued outstanding topline survival and clinical benefit data in advanced metastatic breast cancer patients treated Bria-IMT™ in combination with an immune check point inhibitor (CPI).
  • The data is being revealed at the 2023 San Antonio Breast Cancer Symposium® held at Henry B. Gonzalez Convention Center, San Antonio, TX.
  • In summary, the consistent topline survival and clinical benefits support BriaCell’s hypothesis of additive and/or synergistic effects of immune check point inhibitors with Bria-IMT™ and support the ongoing pivotal study of our combination regimen in the treatment of advanced metastatic breast cancer.

Gentherm Announces Laura Kowalchik as New Independent Director

Retrieved on: 
Wednesday, December 6, 2023
Audit committee, Business administration, Trustee, Chairperson, Dayco, CPI, University, Temperature, Communication, Treasurer, Information technology, Management

Prior to joining CPI, Kowalchik served as the Chief Financial Officer of Dayco Incorporated, a global manufacturer and distributor of engine drive systems and aftermarket services for automotive, heavy-duty, and industrial markets.

Key Points: 
  • Prior to joining CPI, Kowalchik served as the Chief Financial Officer of Dayco Incorporated, a global manufacturer and distributor of engine drive systems and aftermarket services for automotive, heavy-duty, and industrial markets.
  • Before Dayco, she served as the Chief Financial Officer of Kenwal Steel Corp., a flat rolled steel service center primarily for the automotive industry.
  • “On behalf of the Board, I am happy to welcome Laura to Gentherm,” said Ronald Hundzinski, Chair of the Board of Gentherm.
  • She has a Bachelor of Science in Business Administration from the University of Richmond and a Master of Business Administration from Indiana University.

Gradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer Treatment

Retrieved on: 
Tuesday, December 5, 2023
Patient, Immunotherapy, Science, Rated R, Neoplasm, Survival, Immune system, Ovarian cancer, Principal, Research, Lung cancer, Paper, DNA, MD, Doctor of Philosophy, HRP, CPI, Randomized controlled trial, University, PARP, TMB, RFS, DNA repair, Ovary, Biomarker, Sequence, Cell, Meta-analysis, Research institute, Pharmaceutical industry

It reviews the potential limitations of certain immunotherapies designed without explicit consideration of clonal neoantigens.

Key Points: 
  • It reviews the potential limitations of certain immunotherapies designed without explicit consideration of clonal neoantigens.
  • This may also explain why clonal neoantigen targeting immunotherapies like Gradalis’ Vigil have shown longer-term overall survival benefits in a randomized controlled trial of patients with solid tumors.
  • Clonal mutations expressed on the cancer surface provide a distinguishing difference between cancer cells and normal non-cancer cells.
  • Emerging research shows that targeting clonal mutations may be critical in achieving a durable clinical benefit,” stated John Nemunaitis, MD, Chief Scientific Officer of Gradalis and co-author of the paper.

Azrieli Group Reports Q3/2023 Results

Retrieved on: 
Monday, November 27, 2023
Bank Leumi, Sale, Azrieli Group, TEL, Hope, CPI, Motion, Commerce, Growth, Investment, NOI, Commercial property

The increase was partially offset by non-inclusion of Compass’s results already in the current quarter.

Key Points: 
  • The increase was partially offset by non-inclusion of Compass’s results already in the current quarter.
  • TEL AVIV, Israel, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Danna Azrieli, Chairwoman of Azrieli Group, said: “The State of Israel is in the midst of a war, and Azrieli Group is entirely committed to the effort and to civil aid on all fronts.
  • We will continue acting on this commitment while maintaining financial strength and responsible conduct in these challenging times, which create both a complex business environment and opportunities.”
    Eyal Henkin, CEO of Azrieli Group, said: “As we mobilize and provide resources, Azrieli Group is closing another good quarter with continued growth in all parameters.
  • The sale of the Group’s minority holdings in Compass reflects a gross yield of x2.5 on the investment (in total, Azrieli Group invested in Compass approx.

CPI Aerostructures Receives $4.4M Orders from Embraer for Engine Inlet Assemblies

Retrieved on: 
Tuesday, November 21, 2023
Aero, CPI, Embraer, Embraer Phenom 300, CPI Aerostructures, Long-Term Capital Management, ERJ, Aerostructure

EDGEWOOD, N.Y., Nov. 21, 2023 (GLOBE NEWSWIRE) -- CPI Aerostructures, Inc. (“CPI Aero®” or the “Company”) (NYSE American: CVU) announced that Embraer S.A. of Brazil (NYSE: ERJ) has placed several additional orders against a previously announced Long Term Agreement to manufacture engine inlet assemblies for the Embraer Phenom 300 business jets.

Key Points: 
  • EDGEWOOD, N.Y., Nov. 21, 2023 (GLOBE NEWSWIRE) -- CPI Aerostructures, Inc. (“CPI Aero®” or the “Company”) (NYSE American: CVU) announced that Embraer S.A. of Brazil (NYSE: ERJ) has placed several additional orders against a previously announced Long Term Agreement to manufacture engine inlet assemblies for the Embraer Phenom 300 business jets.
  • These new orders will see deliveries continue into 2024.
  • “CPI Aero is proud to be part of the successful Phenom 300 program where we continue to demonstrate our capabilities in assembly & integration of complex, mixed-commodity Aerostructures.
  • During the last 10+ years, we have delivered over 1,600 Engine Inlet Assemblies and fully expect to continue serving this important customer beyond 2024,” stated Dorith Hakim, CPI Aero’s CEO & President.

CME Group to Expand Gold, Silver and Copper Short-Term Options Expiries

Retrieved on: 
Tuesday, December 19, 2023
ADV, CME Group, LTD, CME, Standard, City, Financial services, CPI, Metal, NYMEX, CBOT, S&P Dow Jones Indices, COMEX, Growth, Fed, EBS, OTC, New York Mercantile Exchange, S&P, Chicago Board of Trade, Gold

CHICAGO, Dec. 19, 2023 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced that it will expand its suite of short-term metals options to include Tuesday and Thursday expiries for Gold, Silver, and Copper, pending regulatory review.

Key Points: 
  • CHICAGO, Dec. 19, 2023 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced that it will expand its suite of short-term metals options to include Tuesday and Thursday expiries for Gold, Silver, and Copper, pending regulatory review.
  • In May 2023, CME Group launched Monday and Wednesday expiries on Weekly Gold, Silver and Copper Weekly options.
  • 25% of Silver, Copper and Gold Weekly options volume now occurs during non-U.S. trading hours.
  • Gold, Silver and Copper Weekly options are listed by and subject to the rules of COMEX.

EQS-News: CPI PROPERTY GROUP – Partial Sale of IMMOFINANZ Shares

Retrieved on: 
Monday, December 25, 2023
Investment, CPI, Sale, Security (finance)

CPI PROPERTY GROUP (“CPIPG” or the “Group”) is pleased to announce a small transaction which enhances liquidity while preserving strategic flexibility.

Key Points: 
  • CPI PROPERTY GROUP (“CPIPG” or the “Group”) is pleased to announce a small transaction which enhances liquidity while preserving strategic flexibility.
  • Recently, CPIPG was approached by Petrus Advisers Investments Fund L.P. (“PAIF”), a London-based investment manager and current shareholder of IMMOFINANZ AG ("IMMOFINANZ"), about increasing their ownership stake.
  • CPIPG agreed to sell 2,575,000 shares of IMMOFINANZ to PAIF, equivalent to 1.86% of the total outstanding.
  • The sale provides CPIPG with additional liquidity, while the call option gives the Group flexibility on future strategic plans for IMMOFINANZ.

EQS-News: CPI PROPERTY GROUP – Sale of two Retail Properties to IMMOFINANZ AG

Retrieved on: 
Friday, December 22, 2023
Sale, CPI, Czech Republic

CPI PROPERTY GROUP (“CPIPG” or the “Company”) is pleased to announce the sale of the Olympia Pilsen shopping centre and a retail park in the Czech Republic to IMMOFINANZ.

Key Points: 
  • CPI PROPERTY GROUP (“CPIPG” or the “Company”) is pleased to announce the sale of the Olympia Pilsen shopping centre and a retail park in the Czech Republic to IMMOFINANZ.
  • The Olympia Pilsen Shopping Center is located on the southeast border of Pilsen and has more than 120 shops on 41,000 m² of space.
  • The transaction technically qualifies as a related party transaction because CPIPG consolidates IMMOFINANZ.
  • As a related party disposal, this sale is not included in CPIPG’s €2 billion external disposal pipeline.

EQS-News: CPI PROPERTY GROUP – Muddy Waters Report

Retrieved on: 
Thursday, December 21, 2023
CPI, Uncertainty, Muddy Waters, Security (finance)

CPI PROPERTY GROUP (hereinafter “CPIPG”, the “Company” or together with its subsidiaries the “Group”), a leading European landlord, notes today the publication of a report by Muddy Waters.

Key Points: 
  • CPI PROPERTY GROUP (hereinafter “CPIPG”, the “Company” or together with its subsidiaries the “Group”), a leading European landlord, notes today the publication of a report by Muddy Waters.
  • As any reader can see, Muddy Waters conducts detailed analysis, and puts effort into telling a compelling and engaging story to suit their needs.
  • We believe that Muddy Waters is categorically wrong about CPIPG.
  • CPIPG understands that a second report by Muddy Waters will be released soon, and we anticipate more unpleasant and untrue statements will be made.